Prior to clinical testing, the BAT was applied to evaluate the propensity of MOv18 IgE to activate basophils from patients with ovarian cancer, the primary malignant indication for folate receptor-α-targeted treatments. The gene discussed is IGHE; the disease is ovarian carcinoma.